Dr. Steven T. Rosen, MD

Dr. Rosen practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Rosen's NPI, 1811968126, was assigned on January 27, 2006. Dr. Rosen graduated from Feinberg School of Medicine in 1976. Dr. Rosen holds California license G129723.

Dr. Rosen's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Rosen's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Rosen to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosen practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosen's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosen is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Rosen's licenses on file in 3 states: California, Illinois and Maryland.

Dmand AI lists chronic leukemia, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Rosen treats.

CMS data shows 301 Medicare services from Dr. Rosen across 2 procedure codes in 2024, all of them office visits, for 93 Medicare patients. Medicare paid $24,351 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Rosen in 2024. The largest group is 65 to 74, with 51 patients. 72% of them have high cholesterol, and 56% have high blood pressure. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosen's median patient age at 70, with 43% women.

In 2024, Dr. Rosen wrote 107 Medicare Part D claims for 27 patients. 28% of them were for generic drugs. CMS names the drug for 63 of them, across 2 drugs with 11 or more claims each, at $875,714 in total drug cost. In 2020, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Rosen for performance year 2024, reported as part of a group. Dr. Rosen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosen as offering telehealth.

Dmand AI links 523 papers to Dr. Rosen, published from 2001 to 2025. 2024 was the busiest year, with 21. The most frequent topics are Antibodies, Monoclonal, Skin Neoplasms and Antineoplastic Agents. Dr. Rosen has published most often in Blood. Dr. Rosen's most frequent co-authors are Christiane Simone Querfeld, MD, PhD, Timothy M. Kuzel, MD and Jasmine M. Zain, MD.

Dmand AI links Dr. Rosen to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell and Intraocular Lymphoma. Northwestern University sponsors the most, 2.

CMS Open Payments shows 208 general payments to Dr. Rosen from 33 drug and device companies from 2016 to 2025. Royalties and licenses make up the largest share, 53% of the total. Pfizer Inc. paid the most, $71,381.

Dmand AI lists 27 awards for Dr. Rosen, most recently Americas Top Doctors for Cancer in 2015.

Dr. Rosen graduated from Feinberg School of Medicine in 1976. Dr. Rosen is a member of ASCO.

Dr. Rosen is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.